European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with early Alzheimer's disease, reversing its initial decision from four months ago.
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at slowing cognitive decline in patients. In July, the Amsterdam-based European Medicines Agency (EMA) denied recommending approval of the drug made by Eisai and Biogen because it considered the risks - especially bleeding and swelling in the brain - to be greater than the potential benefits in a broad population.
European regulators green light new Alzheimer's drug after first rejecting it
European regulators initially said in July that the drug's benefits did not outweigh its risks. View on euronews
European watchdog partially approves new Alzheimer's drug
Europe's medicines watchdog on Thursday partially approved a marketing request for a long-awaited new treatment for Alzheimer's disease, reversing an earlier decision not to give it the green light.
ScienceAlert on MSN2d
Brain Autopsies Reveal a Potential New Culprit Behind Alzheimer's
University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...
Caring for N.Y.ers with Alzheimer’s
November is Alzheimer’s Awareness Month and New York has the second highest rate of Alzheimer’s disease in the U.S. NYC’s ...
Neuroscience News10h
Alzheimer’s Linked to Key Proteins via Cerebrospinal Fluid Analysis
Using cerebrospinal fluid from living patients, researchers have identified specific proteins and genetic pathways involved ...
‘The Unicorn' at UNTHSC is a gamechanger, say Alzheimer's researchers
Researchers say ‘the Unicorn,’ their invention at the University of Texas Health Science Center, is a game-changer in the ...
KEYT2h
Hundreds of people Walked to End Alzheimer’s at Chase Palm Park, honoring family and friends
A walk meaningful for many people not just today, but everyday to end Alzheimer's held at Chase Palm Park in Santa Barbara. "Alzheimer's disease is ...
Phoenix-based Banner Health receives $74.5 million grant to study Alzheimer's
The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.
verywellhealth13h
What’s the Difference Between Dementia and Alzheimer’s?
Dementia describes symptoms like memory loss in multiple diseases, and Alzheimer’s is the most common form. Here are the key ...
West Central Tribune1d
Reader News: Willmar, Minnesota, Walk to End Alzheimer's event raises $22,900
14, joined together for a common cause: raising money to fund Alzheimer’s Association’s classes and resources for local ...
WJTV Jackson on MSN1d
Alzheimer’s Awareness Month in Mississippi
November is Alzheimer’s Awareness Month. According to the Alzheimer’s Association Mississippi Chapter, nearly 7 million ...
Nasal Spray Could Delay Alzheimer's by Years
An anti-Alzheimer's nasal spray that could delay the progress of the disease by years has been developed by scientists at ...